Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02610283 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery
A Phase 2 study, sponsored by Quark Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 341
- Enrollment target
NCT02610283 is a Phase 2 study that has completed, run by Quark Pharmaceuticals. The registered enrollment target is 341 participants.
The verdict
NCT02610283, a Phase 2 study, has completed, sponsored by Quark Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 341 participants
- Enrollment target
Study Summary
This trial is designed to evaluate QPI-1002 versus placebo for the prevention of AKI in subjects who are at high risk for AKI following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.
Interventions
- DRUG Placebo
- DRUG QPI-1002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02610283
The ClinicalTrials.gov registry entry for NCT02610283 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 341 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quark Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02610283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02610283 about?
NCT02610283 is a clinical study titled "A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery". This trial is designed to evaluate QPI-1002 versus placebo for the prevention of AKI in subjects who are at high risk for AKI following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.
What is the current status of trial NCT02610283?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 341 participants. The study started on 2015-12. Estimated completion is 2018-04.
What interventions are being tested in trial NCT02610283?
The interventions under investigation include: Placebo (DRUG), QPI-1002 (DRUG).
Who is sponsoring clinical trial NCT02610283?
This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.